ABB India Secures Landmark Contract to Automate Reliance Life Sciences’ Biopharmaceutical Facilities

ABB India has achieved a significant milestone by securing a prominent order from Reliance Life Sciences. The objective is to introduce cutting-edge automation and control solutions for Reliance’s upcoming biosimilars and plasma proteins manufacturing units situated in Nashik, Maharashtra.

The comprehensive project involves the complete automation of the manufacturing process, leveraging ABB’s flagship Distributed Control System (DCS) – the Ability™ System 800xA, in addition to Remote I/O systems, Batch Recipe Management, and MES Integration.

Reliance Life Sciences is poised to leverage ABB’s advanced technology suite to achieve several key objectives. These include the attainment of operational excellence, the reduction of time to market for their products, and the assurance of stringent quality control standards throughout their manufacturing operations.

By implementing ABB’s DCS, operating on the latest Windows version, Reliance Life Sciences is set to achieve tangible benefits, including a reduction in the total cost of ownership. ABB’s DCS solution not only delivers seamless automation but also serves as an integration platform, facilitating efficient monitoring of various sections within the manufacturing plants. This capability not only enhances overall plant performance but also streamlines maintenance procedures.

This collaboration marks a significant stride in ABB’s commitment to pushing the boundaries of industrial automation, while simultaneously reinforcing Reliance Life Sciences’ dedication to advancing the biopharmaceutical sector. The collective efforts of these two industry leaders are poised not only to elevate their respective enterprises but also to make a positive and transformative impact on the broader landscape of biopharmaceutical manufacturing and healthcare delivery.

Pearl Global Industries Interim Dividend of Rs.5/-

Board of Directors of the Company at its Meeting held today, August 21 , 2023, have inter-alia, considered, and approved first interim dividend of Rs.5/- per equity share i.e. 50% on face value of Rs. 10/- each for the financial year 2023-24. Such interim Dividend will be paid within 30 days

Eugia Pharma’s Icatibant Injection, 30 mg/3 mL Single-Dose Prefilled Syringe, Secures USFDA Approval

Similar Posts